Bafna Pharmaceuticals (BAFNAPH) 52 Week High Streak Extends to 14 Sessions
- September 30, 2026
- Posted by: Chaitanya Auti
- Category: News
Bafna Pharmaceuticals Ltd. has now traded within 2% of its 52-week high for its fourteenth consecutive session, with the stock moving up 31.66% across the streak. On the latest update, BAFNAPH touched Rs 468.65, matching the day’s high, and the latest Univest data confirms the repeated-high pattern but does not establish a company-specific catalyst for the continued move.
At 19 October 2026 at 9:22 AM IST, the stock was trading above its previous close of Rs 459.50 after opening at Rs 465.00 and moving between Rs 460.00 and Rs 468.65. With a market capitalisation of Rs 1,108.65 crore, the pattern matters because it shows persistence across multiple sessions rather than a one-day price spike, which is what makes a Bafna Pharmaceuticals 52 Week High Streak notable for readers tracking Bafna Pharmaceuticals Share Price and Stock News.
Bafna Pharmaceuticals Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 468.65 |
| Previous Close | Rs 459.5 |
| Today's Move | +Rs 9.15 (+1.99%) |
| Open | Rs 465 |
| High | Rs 468.65 |
| Low | Rs 460 |
| Market Capitalisation | Rs 1,108.65 crore |
Bafna Pharmaceuticals Ltd. (BAFNAPH) traded at Rs 468.65 versus the previous close of Rs 459.5, a rise of 1.99%. The stock opened at Rs 465, reached a high of Rs 468.65 and touched a low of Rs 460.
Bafna Pharmaceuticals Share Price Today shows a firm intraday position, with the stock last traded at Rs 468.65, up Rs 9.15 or 1.99% from the previous close of Rs 459.50. The day opened at Rs 465.00, rose to Rs 468.65 and touched a low of Rs 460.00, leaving the current price at the top of the day’s range and close to the recent yearly high zone.
For traders following Bafna Pharmaceuticals Stock Price movement, the useful detail is not only the percentage change but the fact that Bafna Pharmaceuticals Share Price Update remains anchored near the upper end of the session range. The market capitalisation of Rs 1,108.65 crore places the move in the context of a company that is already being watched closely in Healthcare, while the repeated strength across sessions keeps Bafna Pharmaceuticals Stock Performance in focus for anyone scanning 52 Week High Stocks.
What the Repeated 52-Week Highs Show
The repeated near-high pattern tells a clearer story than a single-day breakout. Bafna Pharmaceuticals 52 Week High Streak has lasted 14 sessions, and the cumulative rise of 31.66% across that stretch shows that the stock has stayed near its one-year peak for an extended period rather than briefly testing it once. That is the main reading investors should take from the streak.
According to the latest Univest data, the move is confirmed as a multi-session pattern, but the data does not identify a company-specific catalyst. That matters because the stock’s repeated presence near its yearly high can be observed without turning the price action into a claim about why it is happening. For readers searching for Bafna Pharmaceuticals New One Year High or Bafna Pharmaceuticals Back to Back 52 Week Highs, the key point is continuity: the market has repeatedly kept the stock in a narrow zone near the top of its yearly range.
Bafna Pharmaceuticals Ltd. (BAFNAPH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,108.65 crore |
| P/E Ratio | 142.35x |
| P/B Ratio | 11.52x |
| ROE | 12.27% |
| ROCE | 11.87% |
| EPS | Rs 3.29 |
| Book Value Per Share | Rs 40.68 |
| Dividend Yield | 0% |
Bafna Pharmaceuticals Ltd. (BAFNAPH) fundamental metrics show P/E 142.35x, P/B 11.52x, ROE 12.27%, ROCE 11.87%. These figures provide context only and are not a buy or sell signal.
Bafna Pharmaceuticals Ltd. has a market capitalisation of Rs 1,108.65 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 142.35x, P/B at 11.52x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.27% and ROCE of 11.87%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 3.29, book value per share of Rs 40.68, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.65x, median ROE of 10.88%, median ROCE of 13.01%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 142.35x |
| Benchmark Median P/E | 26.65x |
| Benchmark Average P/E | 38.51x |
| Benchmark P/E Range | 0x to 629.67x |
| Company P/B Ratio | 11.52x |
| Benchmark Median P/B | 2.78x |
| Company ROE | 12.27% |
| Benchmark Median ROE | 10.88% |
| Company ROCE | 11.87% |
| Benchmark Median ROCE | 13.01% |
| Company Market Capitalisation | Rs 1,108.65 crore |
| Benchmark Median Market Cap | Rs 709.41 crore |
Bafna Pharmaceuticals Ltd. (BAFNAPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Bafna Pharmaceuticals Ltd. (BAFNAPH) has a P/E ratio of 142.35x, which is above the benchmark median of 26.65x, a difference of +434.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Bafna Pharmaceuticals Ltd. (BAFNAPH) has a ROE of 12.27%, which is above the benchmark median of 10.88%, a difference of +12.78%. Bafna Pharmaceuticals Ltd. (BAFNAPH) has a ROCE of 11.87%, which is below the benchmark median of 13.01%, a difference of -8.76%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd. | LINCOLN | 1,094.62 | 11.35 | 1.38 | 12.3 | 16.27 |
| Bajaj Healthcare Ltd. | BAJAJHCARE | 1,144.11 | 45.84 | 2.05 | 4.35 | 7.04 |
| Sigachi Industries Ltd. | SIGACHI | 1,051.97 | 41.49 | 1.99 | -14.75 | -10.72 |
| Bharat Parenterals Ltd. | BPLPHARMA | 1,242.9 | 0 | 3.9 | -8.36 | -1.82 |
| Themis Medicare Ltd. | THEMISMED | 981.33 | 24.55 | 2.33 | 0.29 | 2.56 |
Bafna Pharmaceuticals Ltd. (BAFNAPH) has a P/E ratio of 142.35x compared with the displayed peer median of 24.55x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.27% compares with a peer median of 0.29% across the companies shown in the table. ROCE stood at 11.87% versus the displayed peer median of 2.56%, providing a capital-efficiency comparison. Bafna Pharmaceuticals Ltd. (BAFNAPH) has a market capitalisation of Rs 1,108.65 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Bafna Pharmaceuticals
- Bafna Pharmaceuticals 52 Week High Streak has now run for 14 consecutive sessions, keeping the stock near its one-year peak.
- The cumulative move across the streak is 31.66%, which makes the multi-session pattern easy to track.
- The stock last traded at Rs 468.65, near the top of the day’s range.
- Its P/E of 142.35 and P/B of 11.52 remain well above the industry medians.
- ROE of 12.27% and ROCE of 11.87% give investors a return-ratio backdrop to weigh against the valuation.
About Bafna Pharmaceuticals Ltd.
The latest Bafna Pharmaceuticals Stock News angle is therefore not just about one move in the share price. It is also about how the company’s valuation, earnings ratio and return metrics fit into the broader Healthcare sector and the Pharmaceutical industry. That combination makes the stock relevant for market watchers scanning Stocks At One Year High Today and Stocks In News Today.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Bafna Pharmaceuticals still trading near its one-year high?
Ans. According to latest Univest data, Bafna Pharmaceuticals has stayed near its 52-week high for 14 straight sessions. The data confirms the pattern, but it does not identify a company-specific catalyst for the extended move.
How long is the Bafna Pharmaceuticals 52 Week High Streak?
Ans. The streak has reached a fourteenth consecutive session. That means the stock has remained within 2% of its 52-week high across each of those sessions rather than just briefly touching the zone once.
What is the cumulative move across the streak?
Ans. The cumulative move across the streak is 31.66%. This is the key multi-session figure for readers tracking Bafna Pharmaceuticals 52 Week High Streak rather than just the latest intraday change.
What is Bafna Pharmaceuticals trading at today?
Ans. At 19 October 2026 at 9:22 AM IST, Bafna Pharmaceuticals was trading at Rs 468.65. It was above the previous close of Rs 459.50 after opening at Rs 465.00 and moving between Rs 460.00 and Rs 468.65.
How does the current valuation look versus the industry?
Ans. The stock trades at a P/E of 142.35 and a P/B of 11.52, both well above the industry medians of 26.65 and 2.78. That makes the valuation stand out sharply versus the Pharmaceuticals & Drugs peer set.
What do the return ratios show?
Ans. Bafna Pharmaceuticals reports ROE of 12.27% and ROCE of 11.87%. Those figures are useful because they show the company’s operating returns alongside a much richer valuation profile. The relevant peer median ROE is 10.88%.
How does Bafna Pharmaceuticals compare with peers?
Ans. Peers such as Lincoln Pharmaceuticals and Themis Medicare trade on much lower P/E and P/B multiples. That comparison shows Bafna Pharmaceuticals at a premium to the comparable group on valuation.
What should investors monitor next?
Ans. Investors should watch whether the stock continues to trade near its yearly high, how the valuation compares with further peer updates, and whether future company news changes the current price pattern. The streak itself is confirmed, but the reason behind it is not.
Track Bafna Pharmaceuticals Ltd. (BAFNAPH) Share Price on Univest
Use Bafna Pharmaceuticals Ltd. (BAFNAPH) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.